3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
Shares of Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) jumped in their Hong Kong trading debut on Friday, as the leading drug maker’s new IPO complemented its existing listing in…
Will Trump’s drug order put the brakes on China’s overseas pharma drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
Estenova aims to become a big name in medical aesthetics
The Chinese developer of anti-wrinkle fillers is seeking a cash injection from a Hong Kong share listing to bring its plumping products to the market Key Takeaways: The biotech made…
RNA drug developer Ribo Life targets fresh funding channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in…
Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
BRIEF: Fosun Pharma raises stake in Henlius
Fosun Pharma (2196.HK) announced on Monday that its wholly owned unit, Fosun Pharma Industrial, acquired 21.03 million unlisted shares of its Henlius (2696.HK) subsidiary for HK$517 million ($66.6 million), or…
Recent Articles
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK
600276.SHG
BRIEF: Fosun Pharma raises stake in Henlius
2196.HK
2696.HK
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
